Hedge Funds

Maverick Capital emphasizing biotech and healthcare


Maverick Capital founder Lee Ainslie announced at the firm's annual investor meetings in Dallas and New York last month that Maverick is separating its biotech and healthcare analytical teams.

Effective January 1, Dr. Howard Furst, a current member of the healthcare team, will lead the biotech activities, and David Singer, who founded three public biotech companies and is chairman of Oscient Pharmaceuticals, will also join the Maverick biotech team. Steve Kapp, who now runs both healthcare and biotech stock analysis for $9 billion Maverick, will continue to oversee all other healthcare-related investments.

Under Maverick's structure, Ainslie serves as portfolio